Clinical Advances in the Diagnosis, Treatment and Management of COPD

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Sunovion

Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs and is the third-leading cause of death in the US, following cancer and heart disease. COPD is an incurable and progressive disease so early diagnosis is very important to decrease lung damage and reduce costs. Unfortunately, COPD is substantially under-diagnosed, undertreated, and is devalued as a major health issue. Smoking is the most common contributing cause of COPD in the US and if not treated early on and aggressively, can lead to disability, comorbid conditions, decreased quality of life, and an increased risk of premature death. Spirometry is required for the diagnosis of COPD. Treatment goals of COPD include relieving symptoms, improving health status and quality of life, reducing the number and severity of exacerbations, preventing and treating complications, and ensuring appropriate end-of-life planning and palliation. The recommended guidelines from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) share that all COPD patients should continuously be assessed based on their symptoms, the severity of airflow limitation, frequency of exacerbations, and comorbidities. The updated GOLD report further adds a thorough review of nonpharmacologic treatment options, in addition to receiving influenza and pneumococcal vaccinations to decrease the risk for lower respiratory tract infections.

Upon completion of this activity, participants will be able to:

  • Evaluate the recently updated GOLD 2017 guideline recommendations for assessing chronic obstructive pulmonary disease (COPD) symptoms

  • Describe appropriate diagnostic measures that warrant the use of standardized tools for COPD symptom assessment

  • Analyze the impact of current and novel COPD pharmacologic agents and combination therapies with consideration for cost-effective prevention strategies such as smoking cessation

  • Discuss recent clinical advances in the understanding of COPD pathophysiology, genetics, disease progression, and comorbidities

  • Assess guideline-recommended and evidence-based pharmacologic interventions to reduce COPD symptoms and decrease exacerbations through medication adherence and inhaler techniques

Faculty: Sanjay Sethi, MD, FACP
Professor of Medicine
Assistant Vice President for Health Sciences
Director, Clinical Research Office
Division Chief, Pulmonary/Critical Care/Sleep Medicine
University at Buffalo, State University of New York


Dr. Sethi serves on an advisory board for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sunovion and Theravance. He has received research/grant support from AstraZeneca and GlaxoSmithKline. He serves on the speaker's bureau for Bayer and Boehringer Ingelheim. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Sunovion

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue